The transcription factor CUX1 negatively regulates invasion in castrate resistant prostate cancer.
androgen-independent prostatic cancer
castration-resistant prostatic cancer
neoplasm invasiveness
recurrence
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
03 Mar 2020
03 Mar 2020
Historique:
received:
06
08
2019
accepted:
29
01
2020
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
18
3
2020
Statut:
epublish
Résumé
Metastatic prostate cancer is treated with androgen ablation therapy but progress to castrate resistant prostate cancer (CRPC). This study aimed to investigate the role of CUX1 in CRPC using clinical samples and
Identifiants
pubmed: 32180898
doi: 10.18632/oncotarget.27494
pii: 27494
pmc: PMC7061738
doi:
Types de publication
Journal Article
Langues
eng
Pagination
846-857Informations de copyright
Copyright: © 2020 Dorris et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.
Références
J Clin Oncol. 1999 May;17(5):1474-81
pubmed: 10334533
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
J Immunol. 2019 Feb 15;202(4):1069-1078
pubmed: 30659109
Oncogene. 2007 Aug 30;26(40):5939-49
pubmed: 17369846
Nucleic Acids Res. 2008 Jan;36(1):189-202
pubmed: 18003658
Gene. 2008 Apr 15;412(1-2):84-94
pubmed: 18313863
Cancer Res. 2009 Jun 15;69(12):4937-40
pubmed: 19509232
Br J Cancer. 1999 Sep;81(2):242-51
pubmed: 10496349
Br J Cancer. 2013 Oct 1;109(7):1711-6
pubmed: 24008662
Mol Oncol. 2017 Mar;11(3):251-265
pubmed: 28133913
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Res. 2000 Jul 1;60(13):3650-4
pubmed: 10910081
Oncotarget. 2017 Jun 30;8(42):72021-72030
pubmed: 29069765
Cell Adh Migr. 2010 Jul-Sep;4(3):348-52
pubmed: 20224295
Cancer Biol Ther. 2016 May 3;17(5):526-42
pubmed: 26828826
Cancer Res. 2009 Sep 15;69(18):7188-97
pubmed: 19738070
Gene. 2000 Jan 4;241(1):75-85
pubmed: 10607901
Cancers (Basel). 2018 Oct 11;10(10):
pubmed: 30314329
Gut. 2010 Aug;59(8):1101-10
pubmed: 20442202
J Biol Chem. 2009 Oct 2;284(40):27701-11
pubmed: 19635798
Cancer Cell. 2005 Jun;7(6):521-32
pubmed: 15950902
Prostate. 2017 Sep;77(12):1288-1300
pubmed: 28726241
Prostate. 2004 Feb 15;58(3):259-68
pubmed: 14743465
Sci Rep. 2016 Sep 14;6:32611
pubmed: 27623747
J Biol Chem. 2000 Oct 6;275(40):31325-34
pubmed: 10864926
J Natl Cancer Inst. 2000 Dec 6;92(23):1918-25
pubmed: 11106683
J Biol Chem. 2007 Oct 12;282(41):30216-26
pubmed: 17681953
Prostate. 2013 May;73(7):743-53
pubmed: 23359479
Mol Cell Biol. 2017 Feb 15;37(5):
pubmed: 27956696
Mol Cell Biol. 2001 Sep;21(18):6332-45
pubmed: 11509674
J Biol Chem. 2011 Jan 21;286(3):2155-70
pubmed: 21037323
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
J Clin Oncol. 2011 Sep 20;29(27):3695-704
pubmed: 21859988
Mol Cancer Res. 2007 Sep;5(9):899-907
pubmed: 17855659
Nat Genet. 2014 Jan;46(1):33-8
pubmed: 24316979
Genes Dev. 2010 Sep 15;24(18):1967-2000
pubmed: 20844012
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
J Biol Chem. 2013 Feb 8;288(6):4135-47
pubmed: 23255599
J Biol Chem. 1996 Sep 27;271(39):23907-13
pubmed: 8798622
Cancer Res. 2006 Oct 1;66(19):9492-501
pubmed: 17018605